EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis

Jiashuo Chao, Shanshan Wang, Hao Wang, Nan Zhang, Yunchao Wang, Xu Yang, Chengpei Zhu, Cong Ning, Xinmu Zhang, Jingnan Xue, Longhao Zhang, Mingjian Piao und 4 weitere

Cancer Immunology, Immunotherapy · 2023-11 · 72 (11) · 3717-3726

DOI: 10.1007/s00262-023-03523-2 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 03.10.2023. Verfasst von Jiashuo Chao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medi…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSCO-Hengrui Cancer Research Fund, CAMS Innovation Fund for Medical Sciences, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In clinical practice, some patients with advanced intrahepatic cholangiocarcinoma (ICC) cannot tolerate or refuse chemotherapy due to the toxicity, necessitating alternative treatments. PD-1 blockade combined with lenvatinib showed promising results in phase II studies with small sample size, but there is a lack of data on the routine use with this regimen. This study aimed to evaluate the effectiveness and safety of the regimen in patients with advanced ICC, and to identify predictors for treatment response and prognosis. METHODS: We conducted a retrospective cohort study of patients treated with PD-1 inhibitors plus lenvatinib for advanced ICC between July 2017 and August 2022. The study endpoints were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety. Biomarker analysis for CA19-9 and PD-L1 expression was performed. Exploratory analysis for genetic alternation was conducted. RESULTS: The study included 103 patients. It demonstrated a median PFS of 5.9 months and a median OS of 11.4 months. ORR was 18.4% and DCR was 80.6%. The incidence of grade 3 or 4 adverse events was 50.5%. Positive PD-L1 expression (TPS ≥ 1%) was associated with higher ORR (P = 0.013) and prolonged PFS (P = 0.023). Elevated CA19-9 (> 37 U/ml) was associated with decreased ORR (P = 0.019), poorer PFS (P = 0.005) and OS (P = 0.034). Patients with IDH1 mutations exhibited a favorable response to the treatment (P = 0.011), and patients with TP53 mutations tended to have worse OS (P = 0.031). CONCLUSIONS: PD-1 blockade plus lenvatinib is effective and safe in routine practice. PD-L1 expression and CA19-9 level appear to predict the treatment efficacy. IDH1 mutations might indicate a better treatment response. CLINICAL TRIAL REGISTRATION: NCT03892577.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsHumansB7-H1 AntigenCA-19-9 AntigenCohort StudiesProgrammed Cell Death 1 ReceptorRetrospective StudiesBile Ducts, IntrahepaticPhenylurea CompoundsQuinolines

Stichwörter der Autor:innen

Biliary tract cancerImmunotherapyLiver cancerProgrammed death 1Targeted therapy

Substanzen

B7-H1 AntigenCA-19-9 AntigenProgrammed Cell Death 1 ReceptorlenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing,…
  • Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Nanjing, China.
  • Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Nanjing, China. lvling@njmu.edu.cn.
  • Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. lvling@njmu.edu.cn.

Förderung

  • CSCO-Hengrui Cancer Research Fund
  • CAMS Innovation Fund for Medical Sciences
  • National High Level Hospital Clinical Research Funding
  • CSCO-MSD Cancer Research Fund
  • National Ten-thousand Talent Program

Zitieren

APA

Chao, J., Wang, S., Wang, H., Zhang, N., Wang, Y., Yang, X., Zhu, C., Ning, C., Zhang, X., Xue, J., Zhang, L., Piao, M., Wang, M., Yang, X., Lu, L., & Zhao, H. (2023). Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunology, Immunotherapy, 72(11), 3717-3726. https://doi.org/10.1007/s00262-023-03523-2

Vancouver

Chao J, Wang S, Wang H, Zhang N, Wang Y, Yang X, et al. Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis. Cancer Immunology, Immunotherapy. 2023;72(11):3717-3726. doi:10.1007/s00262-023-03523-2

BibTeX
@article{Chao2023,
  author = {Chao, Jiashuo and Wang, Shanshan and Wang, Hao and Zhang, Nan and Wang, Yunchao and Yang, Xu and Zhu, Chengpei and Ning, Cong and Zhang, Xinmu and Xue, Jingnan and Zhang, Longhao and Piao, Mingjian and Wang, Mingming and Yang, Xiaobo and Lu, Ling and Zhao, Haitao},
  title = {Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2023},
  volume = {72},
  number = {11},
  pages = {3717--3726},
  doi = {10.1007/s00262-023-03523-2}
}
Kostenlos starten →